Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totaling 177,209 shares, a growth of 469.8% from the May 31st total of 31,099 shares. Based on an average trading volume of 6,889,317 shares, the short-interest ratio is presently 0.0 days. Currently, 18.2% of the shares of the company are short sold.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.
View Our Latest Research Report on BJDX
Bluejay Diagnostics Trading Down 0.3%
Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.
Institutional Investors Weigh In On Bluejay Diagnostics
An institutional investor recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 18.47% of the company’s stock.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.
Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.
Featured Stories
- Five stocks we like better than Bluejay Diagnostics
- Uncle Sam Plugs In: Nuclear Energy’s Cash Flow Moment Is Finally Here
- Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout
- 3 Stocks Building the Future of Agentic AI Payments
- This Single Factor Is Holding Back Carvana’s Disruptive Edge
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
